



How similar is this cluster to the other clusters?




What groups of morphological features are distinguishing in the cluster relative to the untreated samples? (maximum of absolute m-score for the features belonging to the same category; m-score defined as median of a feature z-score across genes in the cluster) Black means no feature is available in the category



































Which individual morphological features are distinguishing in the cluster relative to the untreated samples? Blue/Red means the feature has a positive/negative z-score. Size is proportional to the z-score value.





How strongly are genes within the cluster correlated?



| | | | | | | | | |
|--|--------------------|--|---|--|---|---|---|---|
| Compound IDs and common names (where available); blue/red colored box means the matching compound is positively/negatively correlated with the cluster | Chemical structure | Mean pairwise replicates correlation of the compound signature (95th DMSO replicate correlation is 0.52) | Mean ± standard deviation correlation between compound and each gene in cluster; Tables contain data for individual genes | Mean compound rank when scored against genes in cluster using L1000 profiling ± standard deviation; Tables contain data for individual genes | How similar is the compound signature to the gene clusters in this experiment? (Yellow and red lines correspond to top/bottom 1st and 5th percentile DMSO correlation to all the genes) | Common distinguishing feature categories in the compound and genes in the cluster relative to the untreated samples | Distinguishing individual features for the compound relative to untreated samples. Black means a mismatch; i.e. active (= high z-score in magnitude) in the compound, and either inactive (= small z-score in magnitude) or oppositely active in the gene cluster | Number of PubChem assays in which the compound was tested; assays in which the compound was active are itemized |
| BRD-K88597074-001-01-4 PubChem CID : 54618422 | | 0.81 (in 4 replicates) | 0.57 ± 0.03 Treatment Score WWTR1.WT 0.59 YAP1.WT.1 0.57 YAP1.WT.2 0.61 YAP1.WT.3 0.59 YAP1.WT.4 0.59 | 0.705 ± 0.082 Treatment Score WWTR1.WT 0.658 YAP1.WT.1 0.613 YAP1.WT.2 0.587 YAP1.WT.3 0.653 YAP1.WT.4 0.615 | | | | Total number of assays tested in: 36. |
| BRD-K64243825-001-01-5 PubChem CID : 54641063 | | NA (in 1 replicates) | 0.53 ± 0.08 Treatment Score WWTR1.WT 0.43 YAP1.WT.1 0.48 YAP1.WT.2 0.37 YAP1.WT.3 0.47 YAP1.WT.4 0.40 | NA | | | | Total number of assays tested in: 38. |

| | | | | | | | | |
|--|---|------------------------|---|--|--|---|---|---|
| BRD-K13462310-001-01-5 PubChem CID : 54619306 |  | 0.88 (in 4 replicates) | 0.51 ± 0.04 Treatment Score WWTRI.WT 0.51 YAPI.WT.1 0.49 YAPI.WT.2 0.58 YAPI.WT.3 0.48 YAPI.WT.4 0.47 | NA |  |  |  | Total number of assays tested in: 40. |
| BRD-K98716460-001-01-0 PubChem CID : 54646067 |  | NA (in 1 replicates) | 0.50 ± 0.09 Treatment Score WWTRI.WT 0.48 YAPI.WT.1 0.51 YAPI.WT.2 0.56 YAPI.WT.3 0.48 YAPI.WT.4 0.49 | 0.341 ± 0.190 Treatment Score WWTRI.WT 0.340 YAPI.WT.1 0.337 YAPI.WT.2 0.195 YAPI.WT.3 0.619 YAPI.WT.4 0.260 |  |  |  | Total number of assays tested in: 40. |
| BRD-K03331449-001-01-8 PubChem CID : 54619602 |  | 0.68 (in 4 replicates) | 0.50 ± 0.06 Treatment Score WWTRI.WT 0.43 YAPI.WT.1 0.46 YAPI.WT.2 0.59 YAPI.WT.3 0.51 YAPI.WT.4 0.50 | 0.694 ± 0.334 Treatment Score WWTRI.WT 0.608 YAPI.WT.1 0.581 YAPI.WT.2 0.787 YAPI.WT.3 0.142 YAPI.WT.4 0.681 |  |  |  | Total number of assays tested in: 39. |
| BRD-K45378289-001-01-2 PubChem CID : 44617810 |  | 0.76 (in 4 replicates) | 0.49 ± 0.07 Treatment Score WWTRI.WT 0.42 YAPI.WT.1 0.43 YAPI.WT.2 0.59 YAPI.WT.3 0.47 YAPI.WT.4 0.53 | 0.844 ± 0.113 Treatment Score WWTRI.WT 0.750 YAPI.WT.1 0.760 YAPI.WT.2 0.787 YAPI.WT.3 0.860 YAPI.WT.4 0.899 |  |  |  | Total number of assays tested in: 39. |
| BRD-K73357010-001-01-7 PubChem CID : 54632234 |  | 0.67 (in 4 replicates) | 0.49 ± 0.06 Treatment Score WWTRI.WT 0.45 YAPI.WT.1 0.45 YAPI.WT.2 0.57 YAPI.WT.3 0.45 YAPI.WT.4 0.53 | 0.727 ± 0.098 Treatment Score WWTRI.WT 0.656 YAPI.WT.1 0.656 YAPI.WT.2 0.787 YAPI.WT.3 0.860 YAPI.WT.4 0.882 |  |  |  | Total number of assays tested in: 38. |
| BRD-K86038750-001-01-2 PubChem CID : 44483954 |  | 0.88 (in 4 replicates) | 0.48 ± 0.03 Treatment Score WWTRI.WT 0.47 YAPI.WT.1 0.45 YAPI.WT.2 0.52 YAPI.WT.3 0.43 YAPI.WT.4 0.49 | NA |  |  |  | Total number of assays tested in: 42. |
| BRD-K24991044-001-01-3 PubChem CID : 44500869 |  | 0.68 (in 4 replicates) | 0.48 ± 0.06 Treatment Score WWTRI.WT 0.41 YAPI.WT.1 0.45 YAPI.WT.2 0.51 YAPI.WT.3 0.41 YAPI.WT.4 0.46 | NA |  |  |  | Total number of assays tested in: 47. Active in the following assays: ● MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01 Inhibitor.Dose:CherryPick.Activity (AID 743317) |
| BRD-K57140889-001-01-5 PubChem CID : 54632228 |  | 0.78 (in 4 replicates) | 0.47 ± 0.06 Treatment Score WWTRI.WT 0.41 YAPI.WT.1 0.45 YAPI.WT.2 0.58 YAPI.WT.3 0.43 YAPI.WT.4 0.47 | 0.681 ± 0.294 Treatment Score WWTRI.WT 0.717 YAPI.WT.1 0.669 YAPI.WT.2 0.787 YAPI.WT.3 0.111 YAPI.WT.4 0.851 |  |  |  | Total number of assays tested in: 35. |

| Treatment | Score |
|-----------|-------|
| WWTR1.WT | -0.41 |
| YAP1.WT.1 | -0.61 |
| YAP1.WT.2 | -0.49 |
| YAP1.WT.3 | -0.46 |
| YAP1.WT.4 | -0.47 |






Total number of assays tested in: 41.
Active in the following assays:

- MLPCN_ERAP1_Measured_in_Biochemical_System_Using_Plate_Reader - 701601_Inhibitor_Dose_CherryPick_Activity (AID: 743317)



The chemical structure shows a large macrocyclic ring with several functional groups. On the left, there is a sulfonate group (-SO₃⁻) attached to a phenyl ring. The macrocycle itself contains a carbonyl group (C=O) and a quaternary ammonium group (-N⁺(CH₃)₃) which is paired with a counterion (represented by a red circle). The macrocycle is also substituted with a long alkyl chain and a hydroxyl group (-OH).

| Treatment | Score |
|-----------|-------|
| WWTR1.WT | -0.38 |
| YAP1.WT.1 | -0.61 |
| YAP1.WT.2 | -0.51 |
| YAP1.WT.3 | -0.43 |
| YAP1.WT.4 | -0.47 |












[illegible]

| Treatment | Score |
|-----------|-------|
| WWTR1.WT | -0.51 |
| YAP1.WT.1 | -0.53 |
| YAP1.WT.2 | -0.47 |
| YAP1.WT.3 | -0.36 |
| YAP1.WT.4 | -0.44 |


| Stimulus | Mean Contrast (approx.) |
|--------------|-------------------------|
| 100% gray | 1.5 |
| 100% black | 2.5 |
| 100% white | 3.5 |
| 100% red | 3.5 |
| 100% green | 3.5 |
| 100% blue | 3.5 |
| 100% yellow | 3.5 |
| 100% cyan | 3.5 |
| 100% magenta | 3.5 |
| 100% brown | 3.5 |
| 100% pink | 3.5 |
| 100% orange | 3.5 |
| 100% purple | 3.5 |
| 100% gray | 3.5 |
| 100% black | 3.5 |
| 100% white | 3.5 |
| 100% red | 3.5 |
| 100% green | 3.5 |
| 100% blue | 3.5 |
| 100% yellow | 3.5 |
| 100% cyan | 3.5 |
| 100% magenta | 3.5 |
| 100% brown | 3.5 |
| 100% pink | 3.5 |
| 100% orange | 3.5 |
| 100% purple | 3.5 |



Total number of assays tested in: 31.

| BRD-K5325530-001-01-8 PubChem CID : 54618578 |  | 0.75 (in 4 replicates) | <div>-0.46 ± 0.06</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>WWTR.WT</td><td>-0.46</td></tr><tr><td>VAP1.WT.1</td><td>-0.35</td></tr><tr><td>VAP1.WT.2</td><td>-0.45</td></tr><tr><td>VAP1.WT.3</td><td>-0.42</td></tr><tr><td>VAP1.WT.4</td><td>-0.47</td></tr></table> <div>0.723 ± 0.217</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>WWTR.WT</td><td>0.723</td></tr><tr><td>VAP1.WT.1</td><td>0.344</td></tr><tr><td>VAP1.WT.2</td><td>0.860</td></tr><tr><td>VAP1.WT.3</td><td>0.771</td></tr><tr><td>VAP1.WT.4</td><td>0.895</td></tr></table> | Treatment | Score | WWTR.WT | -0.46 | VAP1.WT.1 | -0.35 | VAP1.WT.2 | -0.45 | VAP1.WT.3 | -0.42 | VAP1.WT.4 | -0.47 | Treatment | Score | WWTR.WT | 0.723 | VAP1.WT.1 | 0.344 | VAP1.WT.2 | 0.860 | VAP1.WT.3 | 0.771 | VAP1.WT.4 | 0.895 |  |  |  <p>Total number of assays tested in: 39 Active in the following assays:</p> <ul style="list-style-type: none">Small molecule inhibitors of miR122 Measured in Cell-Based System Using Plate Reader - 2144-01 Activator.SinglePoint.HTS Activity (AID 623901)Small molecule inhibitors of miR122 Measured in Cell-Based System Using Plate Reader - 2144-01 Activator.Dose.CherryPick Activity (AID 651956) |
|---|---|------------------------|--|-----------|-------|---------|-------|-----------|-------|-----------|-------|-----------|-------|-----------|-------|--|---|--|-------|-----------|-------|-----------|-------|-----------|-------|-----------|-------|---|--|--|
| Treatment | Score | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| WWTR.WT | -0.46 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.1 | -0.35 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.2 | -0.45 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.3 | -0.42 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.4 | -0.47 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Treatment | Score | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| WWTR.WT | 0.723 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.1 | 0.344 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.2 | 0.860 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.3 | 0.771 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.4 | 0.895 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| BRD-K43014865-001-01-7 PubChem CID : 44617302 |  | 0.90 (in 4 replicates) | <div>-0.45 ± 0.08</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>WWTR.WT</td><td>-0.42</td></tr><tr><td>VAP1.WT.1</td><td>-0.48</td></tr><tr><td>VAP1.WT.2</td><td>-0.41</td></tr><tr><td>VAP1.WT.3</td><td>-0.36</td></tr><tr><td>VAP1.WT.4</td><td>-0.46</td></tr></table> <div>NA</div> | Treatment | Score | WWTR.WT | -0.42 | VAP1.WT.1 | -0.48 | VAP1.WT.2 | -0.41 | VAP1.WT.3 | -0.36 | VAP1.WT.4 | -0.46 |  |  |  <p>Total number of assays tested in: 40 Active in the following assays:</p> <ul style="list-style-type: none">HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01 Inhibitor.SinglePoint.HTS Activity (AID 720706) | | | | | | | | | | | | |
| Treatment | Score | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| WWTR.WT | -0.42 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.1 | -0.48 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.2 | -0.41 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.3 | -0.36 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.4 | -0.46 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| BRD-K69411451-001-05-5 MLS000521139 AC1NOQEF HMS2456K10 ZINC220503 SMR000131548 EU-0064772 PubChem CID : 5092614 |  | NA (in 1 replicates) | <div>-0.45 ± 0.06</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>WWTR.WT</td><td>-0.48</td></tr><tr><td>VAP1.WT.1</td><td>-0.51</td></tr><tr><td>VAP1.WT.2</td><td>-0.39</td></tr><tr><td>VAP1.WT.3</td><td>-0.42</td></tr><tr><td>VAP1.WT.4</td><td>-0.41</td></tr></table> <div>NA</div> | Treatment | Score | WWTR.WT | -0.48 | VAP1.WT.1 | -0.51 | VAP1.WT.2 | -0.39 | VAP1.WT.3 | -0.42 | VAP1.WT.4 | -0.41 |  |  |  <p>Total number of assays tested in: 682. Active in the following assays:</p> <ul style="list-style-type: none">A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease (AID 624483) | | | | | | | | | | | | |
| Treatment | Score | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| WWTR.WT | -0.48 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.1 | -0.51 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.2 | -0.39 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.3 | -0.42 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.4 | -0.41 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| BRD-K31826120-001-01-9 PubChem CID : 44496416 |  | 0.75 (in 4 replicates) | <div>-0.45 ± 0.09</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>WWTR.WT</td><td>-0.33</td></tr><tr><td>VAP1.WT.1</td><td>-0.55</td></tr><tr><td>VAP1.WT.2</td><td>-0.47</td></tr><tr><td>VAP1.WT.3</td><td>-0.40</td></tr><tr><td>VAP1.WT.4</td><td>-0.48</td></tr></table> <div>NA</div> | Treatment | Score | WWTR.WT | -0.33 | VAP1.WT.1 | -0.55 | VAP1.WT.2 | -0.47 | VAP1.WT.3 | -0.40 | VAP1.WT.4 | -0.48 |  |  |  <p>Total number of assays tested in: 42</p> | | | | | | | | | | | | |
| Treatment | Score | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| WWTR.WT | -0.33 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.1 | -0.55 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.2 | -0.47 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.3 | -0.40 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.4 | -0.48 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| BRD-A61437901-001-06-4 AC1MELUG MLS001034555 HMS2964O04 STK056804 SMR000664698 ST50589848 PubChem CID : 2905407 |  | 0.92 (in 2 replicates) | <div>-0.45 ± 0.08</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>WWTR.WT</td><td>-0.40</td></tr><tr><td>VAP1.WT.1</td><td>-0.36</td></tr><tr><td>VAP1.WT.2</td><td>-0.45</td></tr><tr><td>VAP1.WT.3</td><td>-0.35</td></tr><tr><td>VAP1.WT.4</td><td>-0.47</td></tr></table> <div>NA</div> | Treatment | Score | WWTR.WT | -0.40 | VAP1.WT.1 | -0.36 | VAP1.WT.2 | -0.45 | VAP1.WT.3 | -0.35 | VAP1.WT.4 | -0.47 |  |  |  <p>Total number of assays tested in: 505. Active in the following assays:</p> <ul style="list-style-type: none">Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). (AID 1861)Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication (AID 1885)Fluorescence-based confirmation cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). (AID 1952)Luminescence Cell-Based/Microorganism Dose Confirmation HTS to Identify Inhibitors of T.Cruzi Replication (AID 2044)Fluorescence-based counterscreen for antagonists of the G-protein coupled receptor 7 (GPR7): cell-based high throughput screening assay to identify antagonists of the melanin-concentrating hormone receptor 1 (MCH1R1) (AID 2148)Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR). (AID 2435)Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R) (AID 2797)Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors (AID 504326)Antagonist of Human D 1 Dopamine Receptor: qHTS (AID 504652)Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS (AID 504660)Primary qHTS for delayed death inhibitors of the malarial parasite plasid, 48 hour incubation (AID 504832)Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1) (AID 588814)Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHO-K1 cell line (AID 602248)Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5) (AID 624037)Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4) (AID 624127)Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1) (AID 624466)Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1) (AID 624467)qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS (AID 720551)qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS (AID 720553)qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS (AID 720579) | | | | | | | | | | | | |
| Treatment | Score | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| WWTR.WT | -0.40 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.1 | -0.36 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.2 | -0.45 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.3 | -0.35 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.4 | -0.47 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| BRD-K27173348-001-01-8 PubChem CID : 44616695 |  | 0.82 (in 4 replicates) | <div>-0.44 ± 0.07</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>WWTR.WT</td><td>-0.40</td></tr><tr><td>VAP1.WT.1</td><td>-0.37</td></tr><tr><td>VAP1.WT.2</td><td>-0.39</td></tr><tr><td>VAP1.WT.3</td><td>-0.44</td></tr><tr><td>VAP1.WT.4</td><td>-0.43</td></tr></table> <div>NA</div> | Treatment | Score | WWTR.WT | -0.40 | VAP1.WT.1 | -0.37 | VAP1.WT.2 | -0.39 | VAP1.WT.3 | -0.44 | VAP1.WT.4 | -0.43 |  |  |  <p>Total number of assays tested in: 20</p> | | | | | | | | | | | | |
| Treatment | Score | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| WWTR.WT | -0.40 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.1 | -0.37 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.2 | -0.39 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.3 | -0.44 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| VAP1.WT.4 | -0.43 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

BRD-K28901743-001-05-3
ZINC01748812
AC1LTAWC
MLS000552933
ZINC1748812
CCG-15676
STL331422
BAS 00558059
SMR000175471
ST50181975
PubChem CID : 1555494






NA (in 1 replicates)

-0.44 ± 0.08

| Treatment | Score |
|-----------|-------|
| WWTR-WT | -0.46 |
| YAP1-WT.1 | -0.56 |
| YAP1-WT.2 | -0.39 |
| YAP1-WT.3 | -0.38 |
| YAP1-WT.4 | -0.45 |

NA



- Total number of assays tested in: 626. Active in the following assays:
- Screen for Chemicals that Extend Yeast Lifespan (AID 775)
 - uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay (AID 463190)
 - Single concentration confirmation of small molecule inhibitors of tim10-1 yeast via a luminescent assay (AID 463213)
 - Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis (AID 588726)
 - Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen (AID 652039)
 - Fluorescence Intensity-based biochemical primary high throughput confirmation assay to identify activators of kallikrein-7 (K7) zymogen (AID 686949)
 - Counterscreen for activators of kallikrein-7 (K7) zymogen: Fluorescence intensity-based biochemical high throughput counterscreen assay for activators that optically interfere with measurement of EDANS-DABCYL fluorescence (AID 686952)